| Jonathan Douglas Jaffe, DO | |
|
Medical Center Blvd, Winston Salem, NC 27157-0001 | |
| (336) 716-2255 | |
| Not Available |
| Full Name | Jonathan Douglas Jaffe |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 17 Years |
| Location | Medical Center Blvd, Winston Salem, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023289378 | NPI | - | NPPES |
| 5919042 | Medicaid | NC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207LP2900X | Anesthesiology - Pain Medicine | 2010-01825 (North Carolina) | Secondary |
| 207L00000X | Anesthesiology | 2010-01825 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Wakemed, Cary Hospital | Cary, NC | Hospital |
| Wakemed, Raleigh Campus | Raleigh, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| East Carolina Anesthesia Associates Pllc | 5092720813 | 464 |
News Archive
Merck, known as MSD outside the United States and Canada, and Astellas US LLC, the U.S. subsidiary of Astellas Pharma Inc. today announced that they have entered into an agreement under which Merck, through a subsidiary, will acquire the exclusive rights to develop and commercialize the investigational intravenous formulation of vernakalant (vernakalant i.v.) in Canada, Mexico and the United States from Astellas.
A new diagnostic test that uses a scientific technique known as metabolomic analysis may be a safe and easy screening method that could improve the prognosis of patients with pancreatic cancer through earlier detection.
A new Yale University study looks at why there is such a big difference in the mortality rates among patients treated for heart attacks in hospitals across the country. The study appears in the March issue of the Annals of Internal Medicine.
TrovaGene, Inc., a developer of transrenal molecular diagnostics, confirmed today that it regained ownership of its worldwide rights and control over its patent estate for transrenal technology for non-invasive prenatal applications and cancer through the termination of a license agreement between TrovaGene and Sequenom, Inc.
› Verified 5 days ago
| Entity Name | Wake Forest University Health Sciences |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003803032 PECOS PAC ID: 4486564952 Enrollment ID: O20031105000436 |
News Archive
Merck, known as MSD outside the United States and Canada, and Astellas US LLC, the U.S. subsidiary of Astellas Pharma Inc. today announced that they have entered into an agreement under which Merck, through a subsidiary, will acquire the exclusive rights to develop and commercialize the investigational intravenous formulation of vernakalant (vernakalant i.v.) in Canada, Mexico and the United States from Astellas.
A new diagnostic test that uses a scientific technique known as metabolomic analysis may be a safe and easy screening method that could improve the prognosis of patients with pancreatic cancer through earlier detection.
A new Yale University study looks at why there is such a big difference in the mortality rates among patients treated for heart attacks in hospitals across the country. The study appears in the March issue of the Annals of Internal Medicine.
TrovaGene, Inc., a developer of transrenal molecular diagnostics, confirmed today that it regained ownership of its worldwide rights and control over its patent estate for transrenal technology for non-invasive prenatal applications and cancer through the termination of a license agreement between TrovaGene and Sequenom, Inc.
› Verified 5 days ago
| Entity Name | East Carolina Anesthesia Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205996519 PECOS PAC ID: 5092720813 Enrollment ID: O20060215000791 |
News Archive
Merck, known as MSD outside the United States and Canada, and Astellas US LLC, the U.S. subsidiary of Astellas Pharma Inc. today announced that they have entered into an agreement under which Merck, through a subsidiary, will acquire the exclusive rights to develop and commercialize the investigational intravenous formulation of vernakalant (vernakalant i.v.) in Canada, Mexico and the United States from Astellas.
A new diagnostic test that uses a scientific technique known as metabolomic analysis may be a safe and easy screening method that could improve the prognosis of patients with pancreatic cancer through earlier detection.
A new Yale University study looks at why there is such a big difference in the mortality rates among patients treated for heart attacks in hospitals across the country. The study appears in the March issue of the Annals of Internal Medicine.
TrovaGene, Inc., a developer of transrenal molecular diagnostics, confirmed today that it regained ownership of its worldwide rights and control over its patent estate for transrenal technology for non-invasive prenatal applications and cancer through the termination of a license agreement between TrovaGene and Sequenom, Inc.
› Verified 5 days ago
| Entity Name | Wake Forest Emergency Providers |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396216735 PECOS PAC ID: 7012819816 Enrollment ID: O20190312003619 |
News Archive
Merck, known as MSD outside the United States and Canada, and Astellas US LLC, the U.S. subsidiary of Astellas Pharma Inc. today announced that they have entered into an agreement under which Merck, through a subsidiary, will acquire the exclusive rights to develop and commercialize the investigational intravenous formulation of vernakalant (vernakalant i.v.) in Canada, Mexico and the United States from Astellas.
A new diagnostic test that uses a scientific technique known as metabolomic analysis may be a safe and easy screening method that could improve the prognosis of patients with pancreatic cancer through earlier detection.
A new Yale University study looks at why there is such a big difference in the mortality rates among patients treated for heart attacks in hospitals across the country. The study appears in the March issue of the Annals of Internal Medicine.
TrovaGene, Inc., a developer of transrenal molecular diagnostics, confirmed today that it regained ownership of its worldwide rights and control over its patent estate for transrenal technology for non-invasive prenatal applications and cancer through the termination of a license agreement between TrovaGene and Sequenom, Inc.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jonathan Douglas Jaffe, DO Po Box 344, Winston Salem, NC 27102-0344 Ph: (336) 716-2255 | Jonathan Douglas Jaffe, DO Medical Center Blvd, Winston Salem, NC 27157-0001 Ph: (336) 716-2255 |
News Archive
Merck, known as MSD outside the United States and Canada, and Astellas US LLC, the U.S. subsidiary of Astellas Pharma Inc. today announced that they have entered into an agreement under which Merck, through a subsidiary, will acquire the exclusive rights to develop and commercialize the investigational intravenous formulation of vernakalant (vernakalant i.v.) in Canada, Mexico and the United States from Astellas.
A new diagnostic test that uses a scientific technique known as metabolomic analysis may be a safe and easy screening method that could improve the prognosis of patients with pancreatic cancer through earlier detection.
A new Yale University study looks at why there is such a big difference in the mortality rates among patients treated for heart attacks in hospitals across the country. The study appears in the March issue of the Annals of Internal Medicine.
TrovaGene, Inc., a developer of transrenal molecular diagnostics, confirmed today that it regained ownership of its worldwide rights and control over its patent estate for transrenal technology for non-invasive prenatal applications and cancer through the termination of a license agreement between TrovaGene and Sequenom, Inc.
› Verified 5 days ago
Craig Michael Combs, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: Medical Center Blvd, Winston Salem, NC 27157 Phone: 336-716-2255 | |
Dr. Susan Elizabeth Atkin, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: Medical Center Blvd, Winston Salem, NC 27157 Phone: 336-716-2255 | |
Dr. Adair Quattlebaum Locke, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 145 Kimel Park Dr Ste 120, Winston Salem, NC 27103 Phone: 336-768-3212 | |
Johan Suyderhoud, Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: Medical Center Blvd, Winston Salem, NC 27157 Phone: 336-716-2255 Fax: 336-716-3202 | |
James Joseph O'brien, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: Medical Center Blvd, Winston Salem, NC 27157 Phone: 336-716-2255 | |
Herbert Mynatt Floyd, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: Medical Center Blvd, Winston Salem, NC 27157 Phone: 336-716-2255 | |
Ann E Lawrence, M.D Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Blvd, Winston Salem, NC 27103 Phone: 336-716-7194 |